Individuals with very high initial blood glucose levels or elevated HbA1c may notice more dramatic improvements early on, whilst those with borderline control might experience subtler changes
In response to these findings, in 2018 European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) consensus guidance provides a decision cycle for patient-centered management of T2DM, taking into account not only key patient characteristics (age, weight, CVD, and renal history), but also specific factors such as HbA1c lowering effect, hypoglycemic risk, effect on weight, side effects, complexity, costs, and cardiorenal effects
However, there are situations where medical guidance is important
Dysregulation of these pathways contributes to impaired insulin secretion, altered lipid homeostasis, hyperglycemia, and metabolic dysfunction observed in obesity and type 2 diabetes [1]
Semaglutide is also available as a daily oral tablet thats FDA-approved for weight loss (the Wegovy pill ), though its slightly less effective than the injection
Activity at these receptors affects hunger regulation and blood sugar control
